TITLE

Human papillomavirus 16/18 AS04-adjuvanted vaccine prevented cervical intraepithelial neoplasia in young women

AUTHOR(S)
Nanda, Kavita
PUB. DATE
December 2009
SOURCE
ACP Journal Club;12/15/2009, Vol. 151 Issue 6, p4
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents information about a clinical trial which examines the effectiveness of an AS04-adjuvanted vaccine against human papillomavirus (HPV) 16/18 in preventing cervical intraepithelial neoplasia (CIN) in young women. 18,729 healthy women of 15 to 25 years were selected from 135 centers in 14 countries. The results show that an AS04-adjuvanted vaccine against human papillomavirus 16/18 can prevent CIN in young women.
ACCESSION #
47420849

 

Related Articles

  • Increased screening best option for cervical cancer prevention in Thailand.  // PharmacoEconomics & Outcomes News;9/3/2011, Issue 636, p1 

    The article presents the findings of an analysis which showed that human papillomavirus (HPV) vaccines are unlikely to be cost effective in reducing the problem of cervical cancer in Thailand. It references a study by N. Praditsitthikorn and colleagues, published in the September 2011 issue of...

  • DETECCIÓN DE VIRUS PAPILOMA HUMANO EN LA PREVENCIÓN DEL CÁNCER CÉRVICO-UTERINO. PICCONI, MARÍA ALEJANDRA // Medicina (Buenos Aires);2013, Vol. 73 Issue 6, p585 

    Cervical cancer (CC), which is strongly associated to high-risk human papillomavirus (hr-HPV) infection, continues being a significant health problem in Latin America. The use of conventional cytology to detect precancerous cervical lesions has had no major impact on reducing CC incidence and...

  • Fewer Than Three Doses of Cervical Cancer Vaccine Effective.  // JNCI: Journal of the National Cancer Institute;Oct2011, Vol. 103 Issue 19, pNP 

    The article reveals that less than three doses of the human papillomavirus (HPV) vaccine Cervarix could be just as effective as the standard three-dose regimen in preventive measures against cervical cancer, according to a study published on September 9, 2011 in the "Journal of the National...

  • Vaccibody Targeting HPV Infection via DNA Vaccine. Sheridan, Cormac // BioWorld International;11/14/2012, Vol. 17 Issue 46, p3 

    This article reports on the two million euros contract received by Vaccibody AS from the Norwegian Research Council to develop an effective therapeutic vaccine against human papillomavirus (HPV) infection. The contract will allow the company to take its first DNA-based vaccine, VB10.16, to...

  • HPV Vaccines--Prophylactic, Not Therapeutic. Markowitz, Lauri E. // JAMA: Journal of the American Medical Association;8/15/2007, Vol. 298 Issue 7, p805 

    This editorial comments on a study in this issue which sought to see if human papillomavirus vaccines (HPV) could clear the viral load in patients who already had the disease. The author says because the study showed the vaccine had no effect following infection, it makes it more important to...

  • HPV Vaccine. Stephenson, Joan // JAMA: Journal of the American Medical Association;6/20/2007, Vol. 297 Issue 23, p2578 

    This article examines a study on the human papillomavirus vaccine Gardasil. The vaccine targets 2 HPV strains that cause about 70 percent of cervical cancers. The study found that the vaccine is more effective in preventing precancerous cervical lesions in women who have not been previously...

  • HPV vaccine can help prevent cervical cancer. Melrose, Erica // St. Charles Journal;11/14/2012, Vol. 47 Issue 46, pB10 

    The article discusses how the administration of human papilloma virus vaccines, particularly Gardasil, can help prevent cervical cancer.

  • To Vaccinate or Not to Vaccinate … That Is the Question. Fontaine, Dan // Canadian Journal of Pathology;2010, Vol. 2 Issue 4, p23 

    The author discusses the information on the human papillomavirus vaccines and its significance in preventing cervical cancer.

  • HPV vaccination and the prevention of cervical cancer: a paradigm changing event. Markman, Maurie // Hem/Onc Today;4/25/2009, Vol. 10 Issue 8, p3 

    The author reflects on the importance of data regarding the effectiveness of two diferent human papillomavirus (HPV) vaccination strategies as a rational approach to prevent the development of cervical cancer.

  • One dose of HPV vaccine protected against cervical cancer for 4 years.  // Hem/Onc Today;1/25/2014, Vol. 15 Issue 2, p8 

    The article discusses a study by cancer epidemiologist Mahboobeh Safaeian, published in a 2013 issue of "Cancer Prevention Research," showing that a single dose of the HPV16/18 vaccine maintained an antibody response against cervical cancer among women in Costa Rica for four years.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics